Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of gram-negative rods

Journal of Clinical Microbiology

Volumn 51, Issue 7, 2013, Pages 2385-2387

  Hombach, Michael ^a   Wolfensberger, Aline ^b   Kuster, Stefan P ^b   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; DISK DIFFUSION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; GRAM NEGATIVE BACTERIUM; HEALTH CARE ORGANIZATION; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPECIES DIFFERENTIATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; STANDARDS;

ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE;

EID: 84879440994     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00921-13     Document Type: Article

References (13)

1. European Committee on Antimicrobial Susceptibility Testing. 2010. Breakpoint tables for interpretation of MICs and zone diameters, version 1.1. EUCAST, Växjö, Sweden. http://www.eucast.org/antimicrobial- susceptibility-testing/previous-versions-of-tables/. Accessed 1 March 2013.
2. Clinical Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Document M100-S19. Clinical Laboratory Standards Institute, Wayne, PA.
3. European Committee on Antimicrobial Susceptibility Testing. 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3. EUCAST, Växjö, Sweden. http://www.eucast.org/antimicrobial- susceptibility-testing/previous-versions-of-tables/. Accessed 1 March 2013.
4. Clinical Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. Document M100-S22. Clinical Laboratory Standards Institute, Wayne, PA.
5. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0. EUCAST, Växjö, Sweden. http://www.eucast.org/antimicrobial- susceptibility-testing/previous-versions-of-tables/. Accessed 1 March 2013.
6. Kallen AJ, Hidron AI, Patel J, Srinivasan A. 2010. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect. Control Hosp. Epidemiol. 31:528-531.
7. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pan-drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281.
8. Hombach M, Bloemberg GV, Boettger EC. 2012. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J. Antimicrob. Chemother. 67:622-632.
9. Kuster SP, Ruef C, Zbinden R, Gottschalk J, Ledergerber B, Neuber L, Weber R. 2008. Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. J. Antimicrob. Chemother. 62:1451-1461.
10. Evans HL, Shaffer MM, Hughes MG, Smith RL, Chong TW, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG. 2003. Contact isolation in surgical patients: a barrier to care? Surgery 134:180-188.
11. Saint S, Higgins LA, Nallamothu BK, Chenoweth C. 2003. Do physicians examine patients in contact isolation less frequently? A brief report. Am. J. Infect. Control 31:354-356.
12. Abad C, Fearday A, Safdar N. 2010. Adverse effects of isolation in hospitalized patients: a systematic review. J. Hosp. Infect. 76:97-102.
13. Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V. 2007. Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum beta-lactamase-producing organisms in a non-outbreak setting. J. Hosp. Infect. 65:354-360.